title: Intracavernosal injection and intraurethral therapy for erectile dysfunction.
abstract: Although the search for newer and more effective oral therapies is continually expanding, intracavernosal and intraurethral treatments continue to keep pace and are expected to remain in the clinician's armamentarium in the years to come. Unless there are contraindications, oral therapies are effective, have minimal side effects, and are first-line treatment. Some patients who have failed intraurethral and intracavernosal injection therapies previously have been shown to have successful outcomes with oral sildenafil in 56% to 57% of cases. If oral therapies are ineffective or have undesirable side effects, the intraurethral or intracavernosal routes are the next approach that should be prescribed.
authors.affiliation: Department of Urology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA.
authors.forename: S
authors.initials: S
authors.lastname: Leungwattanakij
authors.forename: V
authors.initials: V
authors.lastname: Flynn
authors.forename: W J
authors.initials: WJ
authors.lastname: Hellstrom
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010208:Papaverine / Q000008:administration & dosage / Q000627:therapeutic use; D010410:Penile Erection / Q000187:drug effects / Q000502:physiology; D010646:Phentolamine / Q000008:administration & dosage / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000317:Adrenergic alpha-Antagonists; D011453:Prostaglandins; D014665:Vasodilator Agents; D010208:Papaverine; D010646:Phentolamine